Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 9,591 shares of the biopharmaceutical company’s stock after buying an additional 3,231 shares during the period. Regeneron Pharmaceuticals accounts for approximately 0.5% of Simplify Asset Management Inc.’s holdings, making the stock its 22nd largest holding. Simplify Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $10,082,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in REGN. SteelPeak Wealth LLC boosted its stake in Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 692 shares during the last quarter. Atria Investments Inc raised its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after acquiring an additional 941 shares during the period. Tri Locum Partners LP boosted its position in shares of Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after acquiring an additional 8,949 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after purchasing an additional 711 shares during the period. Finally, Catalytic Wealth RIA LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $1,334,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.7 %

Shares of NASDAQ REGN traded down $20.92 during midday trading on Friday, hitting $761.59. 214,309 shares of the company’s stock were exchanged, compared to its average volume of 525,231. The company has a market cap of $83.69 billion, a PE ratio of 18.93, a P/E/G ratio of 3.04 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a twelve month low of $760.05 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm’s fifty day simple moving average is $992.70 and its 200-day simple moving average is $1,033.92.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on REGN. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.